MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced that it will present at Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 2:30 pm (ET) in New York, New York. MannKind Corporation (NASDAQ:MNKD) weekly performance is 14.69%. On last trading day company shares ended up $8.90. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 37.52%.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was a big mover last session, as its shares rose roughly 10% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This continues the trend for the company since May 21, as the stock is now up nearly 19%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell -2.47% in last trading session and ended the day on $2.37. FOLD return on assets is -59.30%.Amicus Therapeutics, Inc. (NASDAQ:FOLD) quarterly performance is -5.95%.
Immunomedics, Inc., (NASDAQ:IMMU) announced that the Company will present at two upcoming healthcare conferences, Jefferies 2014 Global Healthcare Conference at 1:30 p.m. Eastern Time on Monday, June 2, 2014, in New York City, and Wells Fargo Securities 2014 Healthcare Conference on Tuesday, June 17, 2014 at 4:05 pm Eastern Time at The InterContinental Hotel in Boston, MA.
Immunomedics, Inc. (NASDAQ:IMMU) shares moved down -4.03% in last trading session and was closed at $3.33, while trading in range of $3.26 – $3.52. Immunomedics, Inc. (NASDAQ:IMMU) year to date (YTD) performance is -27.61%.
GTx, Inc. (NASDAQ:GTXI) announced that management will present a company overview on June 4, 2014, at the Jefferies 2014 Global Healthcare Conference in New York City. The GTx presentation will begin at 1:30 pm EST. GTx, Inc. (NASDAQ:GTXI) ended the last trading day at $1.66. Company weekly volatility is calculated as 7.06% and price to cash ratio as 4.51.GTx, Inc. (NASDAQ:GTXI) showed a positive weekly performance of 20.29%.
For the quarter ended March 31, 2014, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) incurred on May 8, a net loss of $3.2 million, or $0.05 per basic and diluted share, compared to a net loss of $5.0 million, or $0.10 per basic and diluted share for the quarter ended March 31, 2013. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) weekly performance is 3.88%. On last trading day company shares ended up $1.34. Analysts mean target price for the company is $5.69. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) distance from 50-day simple moving average (SMA50) is 8.43%.